Creative Biolabs has announced an integrated approach that connects glycoprotein development with glycan analysis, aiming to help researchers better understand how production decisions affect glycosylation and, consequently, the molecular properties of therapeutic candidates. The company, based in Shirley, New York, provides biotechnology research services spanning therapeutic discovery, glycoengineering, production, and advanced characterization for pharmaceutical, biotechnology, and academic organizations worldwide.
Developing a therapeutic glycoprotein requires more than producing the correct amino acid sequence. Glycosylation can vary with expression systems and production conditions, introducing molecular heterogeneity that may influence protein stability, biological activity, and other molecular properties. As candidates progress through development, researchers need analytical strategies that connect production decisions with glycan-level characterization. Creative Biolabs addresses this need by offering capabilities that span glycoprotein design, production, detection, quantification, structural profiling, and glycan analysis, allowing researchers to examine glycosylation-related attributes alongside development workflows.
The company emphasizes that glycoprotein development and characterization are closely linked. Differences introduced during expression or production may result in changes in glycosylation profiles, while analytical findings can help researchers determine which molecular features require further investigation. By considering development and characterization together, researchers can investigate how production-related variation corresponds with glycosylation patterns rather than treating glycan analysis solely as an endpoint measurement.
Selecting an appropriate analytical strategy starts with defining the research question. Depending on the glycoprotein and development stage, researchers may need to assess overall carbohydrate composition, quantify constituent monosaccharides, compare glycosylation profiles, or investigate glycan structures in greater detail. Creative Biolabs provides carbohydrate analysis services that support these glycoprotein-focused investigations. Available approaches include high-performance anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD), high-performance liquid chromatography (HPLC), capillary electrophoresis (CE), mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and size-exclusion chromatography (SEC). Rather than relying on a single measurement, complementary analytical methods can provide different layers of compositional and structural information.
A practical strategy is to identify the glycosylation attributes relevant to a candidate before selecting analytical methods. For example, when production batches exhibit different glycosylation profiles, monosaccharide composition analysis can provide an initial view of changes in constituent sugars. Additional glycan and structural analyses can then investigate the observed variation in greater detail. This question-driven approach helps researchers select analytical technologies according to specific development challenges rather than applying the same characterization workflow to every glycoprotein candidate.
The importance of this integrated approach lies in its potential to streamline therapeutic development. Glycosylation can influence protein folding, stability, biological activity, and molecular heterogeneity. By connecting development and characterization, researchers can generate analytical data to guide subsequent investigation, potentially leading to more effective and consistent glycoprotein therapeutics. For the pharmaceutical and biotechnology industries, this could mean faster development timelines, reduced costs, and improved product quality. Creative Biolabs' tailored strategies allow complementary technologies to be combined when greater compositional or structural detail is required, offering flexibility to meet diverse research objectives. As the demand for complex biologics grows, such integrated services may become increasingly valuable for organizations seeking to optimize their glycoprotein candidates.
